Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
life sciences
national blog main
abaloparatide
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
amgen
aminolevulinic acid
biotech
boston
boston blog main
boston top stories
drugs
europe blog main
europe top stories
european commission
givosiran
national
onpattro
osteoporosis
patisiran
paul matteis
radius health
rna interference
romosozumab
san francisco blog main
san francisco top stories
stifel financial
teriparatide
ucb
What
approval
2
×
drug
medicine
2
×
nod
2
×
ago
alnylam
amgen
amgen’s
carries
developed
europe
european
fda
heart
indicated
interference
marketing
osteoporosis
pharmaceuticals
quick
raise
risk
rna
rnai
second
seek
speedy
warning
weeks
wins
won’t
Language
unset
Current search:
nod
×
medicine
×
approval
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug